BRACE trial

Research area: Infection and ImmunityInfectious Diseases | Status: Active

This Australian-led study is the world’s largest trial on the off-target effects of Bacille Calmette-Guérin (BCG) vaccine.

The BRACE trial is investigating whether BCG vaccine reduces the incidence of symptomatic and severe COVID-19, as well as other respiratory illnesses and allergic diseases.

Participant FAQs

PhD Opportunities

The BRACE trial is investigating whether BCG vaccine reduces the incidence of symptomatic and severe COVID-19, as well as other respiratory illnesses and allergic diseases.

Participant FAQs

PhD Opportunities

The BRACE trial is investigating whether BCG vaccine reduces the incidence of symptomatic and severe COVID-19, as well as other respiratory illnesses and allergic diseases.

Participant FAQs

PhD Opportunities

Overview

To help prevent severe tuberculosis (TB) in children, BCG vaccine has off-target (non-specific or immunomodulatory) effects. That’s why this multi-centre, randomised controlled clinical trial is working to determine:

Whether the BCG vaccine reduces the incidence of symptomatic and severe COVID-19.

If BCG vaccine reduces the impact of other respiratory illnesses and allergic diseases.

The immunological mechanisms that underlie BCG’s off-target effects, COVID-19 severity and risks.


The safety profile of BCG vaccination and revaccination in adults.

If BCG alters the acquisition of latent TB in healthcare workers.

Biomarkers predictive of COVID-19 risk, severity and vaccine efficacy.


Sub-study

The BRACE COVID-19-specific vaccine Sub-study (BCOS)

The BRACE trial has introduced a sub-study at selected sites in Australia and Brazil to investigate whether it’s possible to predict who remains susceptible to SARS-CoV-2 variants despite previous COVID-19 disease or COVID-19-specific vaccination.

The sub-study will look at whether BCG vaccine, by boosting the immune system, improves the response to Pfizer, AstraZeneca and CoronaVac vaccines.

Read more

brace participants 091121

 

Trial data

So far, the trial has generated:

Trial Symptom Tracker app entries

355,000

Telephonista entries

190,000

BRACE blood samples

25,000


BCOS blood samples

1,900

Clinic visits

26,000

Surveys sent

23,000

 

A cutting-edge study of BCG vaccines off-target effects 

icon 100yo v3>6800
healthcare workers

icon 100yo v336
study sites

icon 100yo v35
countries

 

icon 100yo v3 >360
researchers & staff

icon 100yo v3 >335K
app check-ins

icon 100yo v3 100
year-old vaccine

 

Professor Nigel Curtis in Murdoch Children's Research Institute Annual Showcase 2020.

Can a 100-year-old vaccine protect healthcare workers against COVID-19?

Professor Nigel Curtis is a paediatric infectious diseases physician and clinician scientist and leader of the Infectious Diseases Research Group at the Murdoch Children's Research Institute.

See more BRACE videos on YouTube.

 

Can a 100-year-old vaccine protect healthcare workers against COVID-19?

Professor Nigel Curtis is a paediatric infectious diseases physician and clinician scientist and leader of the Infectious Diseases Research Group at the Murdoch Children's...

Can a 100-year-old vaccine protect healthcare workers against COVID-19?

Professor Nigel Curtis is a paediatric infectious diseases physician and clinician scientist and leader of the Infectious Diseases Research Group at the Murdoch Children's Research Institute.

See more BRACE videos on YouTube.

 

bracesites lockup horizontal
Professor Nigel Curtis

Want to be part of the global effort to help contain this pandemic?

Donate to the BRACE trial